12:00 AM
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Yondelis trabectedin: Phase II data

PharmaMar S.A., Madrid, Spain
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Product: Yondelis trabectedin ( ET-743)
Business: Cancer
Molecular target: DNA
Description: Cytotoxic alkaloid that binds the minor groove of DNA
Indication: Treat unresectable or metastatic liposarcoma or leiomyosarcoma
Endpoint: Time to disease progression (TTP)
Status: Phase II data

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >